Mintz Levin Represents Cleveland BioLabs, Inc. in $23.5 Million Registered Direct Shelf Offering
NEW YORK–(BUSINESS WIRE)–A team of attorneys from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented Cleveland BioLabs, Inc. (NASDAQ:CBLI) in a registered direct shelf offering of $23.5 million of the company’s securities. Cleveland BioLabs, Inc, a biotechnology company involved in developing drugs for multiple medical and defense applications, sold an aggregate of approximately 5.873 million shares of its common stock and warrants exercisable for up to approximately 2.936 million
See original here:
Mintz Levin Represents Cleveland BioLabs, Inc. in $23.5 Million Registered Direct Shelf Offering
Cleveland BioLabs to Raise $23.5 Million in Registered Direct Offering
BUFFALO, NY–(Marketwire – 06/17/11) – Cleveland BioLabs, Inc. (NASDAQ: CBLI – News ) today announced it has received commitments from certain institutional and accredited investors to purchase an aggregate of $23.5 million of the Company’s securities in a registered direct offering. The Company entered into definitive purchase agreements with these investors pursuant to which the Company agreed …
Read more:
Cleveland BioLabs to Raise $23.5 Million in Registered Direct Offering
Cleveland BioLabs to Discuss Recent Developments on September 20 Conference Call
BUFFALO, NY–(Marketwire – September 17, 2010) – Cleveland BioLabs, Inc. ( NASDAQ : CBLI ) today announced that it will host a conference call at 10:00 a.m. EDT on September 20 to discuss recent corporate developments.
The rest is here:
Cleveland BioLabs to Discuss Recent Developments on September 20 Conference Call
Department of Defense Awards Cleveland BioLabs Contract for CBLB502 Fully Valued at $45 Million
BUFFALO, NY–(Marketwire – September 17, 2010) – Cleveland BioLabs, Inc. ( NASDAQ : CBLI ) today announced that it was awarded a $45 million contract (including options), from the United States Department of Defense (DoD) Chemical Biological and Medical Systems (CBMS) Medical Identification and Treatment Systems (MITS) to develop and stockpile CBLB502 as a medical radiation countermeasure.
Follow this link:
Department of Defense Awards Cleveland BioLabs Contract for CBLB502 Fully Valued at $45 Million
Cleveland BioLabs to Present at Rodman & Renshaw 12th Annual Healthcare Conference
BUFFALO, NY–(Marketwire – September 7, 2010) – Cleveland BioLabs, Inc. ( NASDAQ : CBLI ) today announced that the Company is scheduled to present at the Rodman & Renshaw 12 th Annual Healthcare Conference, September 12-15, in New York, NY.
More:
Cleveland BioLabs to Present at Rodman & Renshaw 12th Annual Healthcare Conference
Cleveland BioLabs Appoints Dr. Michael Paterno Director of Clinical Operations
BUFFALO, NY–(Marketwire – June 28, 2010) – Cleveland BioLabs, Inc. ( NASDAQ : CBLI ) today announced that the Company has appointed Michael Paterno, O.D. Director of Clinical Operations. Paterno’s primary responsibility will be to facilitate the clinical program leading to a successful Biologic License Application submission for CBLB502 as a Medical Radiation Countermeasure with the U.S. Food …
See the original post:
Cleveland BioLabs Appoints Dr. Michael Paterno Director of Clinical Operations
Cleveland BioLabs to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference
BUFFALO, NY–(Marketwire – May 11, 2010) – Cleveland BioLabs, Inc. ( NASDAQ : CBLI ) today announced that the Company is scheduled to present at the Rodman & Renshaw 6 th Annual Global Healthcare Conference, May 16-18, in London, UK.
Excerpt from:
Cleveland BioLabs to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference
Cleveland BioLabs Concludes Dosing of Second Safety Study for CBLB502
BUFFALO, NY–(Marketwire – May 10, 2010) – Cleveland BioLabs, Inc. ( NASDAQ : CBLI ) today announced that dosing of healthy volunteers was completed in the second human safety study for CBLB502, a drug under development for the treatment of Acute Radiation Syndrome (ARS).
Read more:
Cleveland BioLabs Concludes Dosing of Second Safety Study for CBLB502
Cleveland BioLabs’ Rachel Levine Interviewed by CorporateProfile.com
BUFFALO, NY–(Marketwire – April 30, 2010) – Cleveland BioLabs, Inc. ( NASDAQ : CBLI ) today announced that an interview with Rachel Levine, Director of Corporate Development and Communications, has been posted to www.corporateprofile.com .
Read more:
Cleveland BioLabs’ Rachel Levine Interviewed by CorporateProfile.com
Cleveland BioLabs to Present at Roth Capital Partners 22nd Annual OC Growth Stock Conference (Marketwire)
BUFFALO, NY–(Marketwire – March 9, 2010) – Cleveland BioLabs, Inc. ( NASDAQ : CBLI ) today announced that the Company is scheduled to present at the Roth Capital Partners 22 nd Annual OC Growth Stock Conference, March 15-17, in Laguna Niguel, CA.
